Resultados de la búsqueda 221-230 of 11275 for Uvetils

1. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...

2. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic ...

3. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving venetoclax with ibrutinib and rituximab with ...

4. Diagnósticos y tratamientos - Mayo Clinic

   Diagnósticos. VEXAS syndrome may be hard to diagnose because of the range of possible symptoms and because the symptoms can be like those of other ...

5. Hematología - Ensayos clínicos - Mayo Clinic

   This phase II trial studies the effect of ascorbic acid and combination chemotherapy in treating patients with lymphoma that has come back (recurrent) or does ...

6. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as obinutuzumab, may ...

7. Hematología - Ensayos clínicos - Mayo Clinic

   The therapy, IC19/1563, uses some of the patients own immune cells, called T cells, to kill cancer. T cells fight infections and, in some cases, can also kill ...

8. Vitiligo

   Grimes PE. Vitiligo: Pathogenesis, clinical features, and diagnosis. https://www.uptodate.com/contents/search. Accessed Dec. 23, 2019. Lebwohl MG, et al.

9. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in ...

10. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in ...